Stay updated on CT-P13 SubQ in IBD: Pharmacokinetics, Efficacy, Safety Clinical Trial
Sign up to get notified when there's something new on the CT-P13 SubQ in IBD: Pharmacokinetics, Efficacy, Safety Clinical Trial page.

Latest updates to the CT-P13 SubQ in IBD: Pharmacokinetics, Efficacy, Safety Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed descriptions of a Phase 1 study comparing subcutaneous and intravenous formulations of CT-P13 for treating Crohn's Disease and Ulcerative Colitis. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference15%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to CT-P13 SubQ in IBD: Pharmacokinetics, Efficacy, Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CT-P13 SubQ in IBD: Pharmacokinetics, Efficacy, Safety Clinical Trial page.